# Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Source: https://onco.cc/trials/nct04468061/  
OnCo record `nct04468061` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of sacituzumab govitecan and pembrolizumab in triple-negative breast cancer, run by Dana-Farber Cancer Institute, now recruiting.

## Summary

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC is a phase 2, randomised interventional study registered as NCT04468061 by Dana-Farber Cancer Institute, with a registry enrolment figure of 110 participants, started 2020-07-20 and due to reach its primary completion in 2027-04-01. Interventions recorded: Sacituzumab Govitecan; Pembrolizumab. Conditions listed: Breast Cancer; Triple Negative Breast Cancer; PD-L1 Negative. Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT04468061
- Phase: 2
- Setting: Saci-IO TNBC: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in PD-L1-negative Metastatic Triple Negative Breast Cancer (TNBC)
- Sponsor: Dana-Farber Cancer Institute
- Enrolled: 110

## Sources

- ClinicalTrials.gov NCT04468061: https://clinicaltrials.gov/study/NCT04468061

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Sacituzumab govitecan](https://onco.cc/drugs/sacituzumab-govitecan/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04468061.json